Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion its initial public offering in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results